Edgestream Partners L.P. Trims Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Edgestream Partners L.P. lessened its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 58.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 22,080 shares of the biopharmaceutical company’s stock after selling 31,442 shares during the quarter. Edgestream Partners L.P.’s holdings in PTC Therapeutics were worth $675,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Choreo LLC raised its position in shares of PTC Therapeutics by 4.1% during the 2nd quarter. Choreo LLC now owns 11,426 shares of the biopharmaceutical company’s stock valued at $356,000 after buying an additional 452 shares during the period. Arizona State Retirement System raised its position in PTC Therapeutics by 3.4% in the second quarter. Arizona State Retirement System now owns 19,301 shares of the biopharmaceutical company’s stock valued at $590,000 after purchasing an additional 636 shares during the period. Diversified Trust Co raised its position in PTC Therapeutics by 5.6% in the second quarter. Diversified Trust Co now owns 15,317 shares of the biopharmaceutical company’s stock valued at $468,000 after purchasing an additional 818 shares during the period. ProShare Advisors LLC raised its position in PTC Therapeutics by 9.3% in the first quarter. ProShare Advisors LLC now owns 18,313 shares of the biopharmaceutical company’s stock valued at $533,000 after purchasing an additional 1,564 shares during the period. Finally, Allspring Global Investments Holdings LLC purchased a new stake in PTC Therapeutics in the first quarter valued at approximately $46,000.

PTC Therapeutics Trading Up 1.3 %

Shares of PTCT stock opened at $36.64 on Friday. The firm has a fifty day moving average price of $33.41 and a 200 day moving average price of $32.43. The company has a market cap of $2.81 billion, a P/E ratio of -4.77 and a beta of 0.64. PTC Therapeutics, Inc. has a 12 month low of $17.53 and a 12 month high of $40.69.

PTC Therapeutics (NASDAQ:PTCT) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.16). The company had revenue of $186.70 million for the quarter, compared to analysts’ expectations of $192.12 million. On average, equities analysts forecast that PTC Therapeutics, Inc. will post -5.09 EPS for the current year.

Insider Buying and Selling at PTC Therapeutics

In other PTC Therapeutics news, CFO Pierre Gravier sold 2,269 shares of the company’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $34.02, for a total value of $77,191.38. Following the completion of the transaction, the chief financial officer now owns 53,531 shares in the company, valued at $1,821,124.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Barclays boosted their target price on PTC Therapeutics from $25.00 to $31.00 and gave the company an “equal weight” rating in a research report on Friday, August 9th. Robert W. Baird assumed coverage on PTC Therapeutics in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $44.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $64.00 target price on shares of PTC Therapeutics in a research report on Tuesday, September 17th. JPMorgan Chase & Co. restated an “overweight” rating and issued a $53.00 price target on shares of PTC Therapeutics in a research note on Thursday, June 20th. Finally, The Goldman Sachs Group boosted their price target on shares of PTC Therapeutics from $18.00 to $32.00 and gave the stock a “sell” rating in a research note on Tuesday, May 28th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, PTC Therapeutics currently has an average rating of “Hold” and a consensus price target of $37.64.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.